Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. DiaSorin S.p.A.
  6. Summary
    DIA   IT0003492391

DIASORIN S.P.A.

(DIA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Borsa Italiana
10/14/2021 10/15/2021 10/18/2021 10/19/2021 10/20/2021 Date
178.9(c) 180.1(c) 179.35(c) 181.5(c) 184.95 Last
116 790 104 906 156 176 126 117 42 426 Volume
+0.22% +0.67% -0.42% +1.20% +1.90% Change
More quotes
Estimated financial data (e)
Sales 2021 1 188 M 1 381 M 1 381 M
Net income 2021 299 M 348 M 348 M
Net Debt 2021 851 M 989 M 989 M
P/E ratio 2021 33,3x
Yield 2021 0,71%
Sales 2022 1 294 M 1 504 M 1 504 M
Net income 2022 285 M 331 M 331 M
Net Debt 2022 660 M 767 M 767 M
P/E ratio 2022 34,9x
Yield 2022 0,77%
Capitalization 9 931 M 11 556 M 11 543 M
EV / Sales 2021 9,07x
EV / Sales 2022 8,19x
Nbr of Employees 2 104
Free-Float 40,3%
More Financials
Company
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac,... 
More about the company
Ratings of DiaSorin S.p.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about DIASORIN S.P.A.
10/07DIASORIN S P A : Publication of the summary report of the votes
PU
10/04DIASORIN S P A : The Extraordinary Shareholders' Meeting of DiaSorin authorizes the conver..
PU
09/18DIASORIN S P A : CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Dete..
PU
07/30DIASORIN S P A : Start up of the treasury shares buy-back plan
PU
07/30Diasorin S.P.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/30DIASORIN : Revenues and Profitability continue upward momentum in the First Half of 2021, ..
PU
07/22DIASORIN S P A : Publication of Information Document under the provisions of the art. 71 o..
PU
07/14DIASORIN S P A : announces completion of the Acquisition of Luminex Corporation
PU
07/09DIASORIN S P A : obtains all approvals necessary to complete the acquisition of Luminex
PU
06/21DIASORIN S P A : The Shareholders' meeting of Luminex Corporation approved the merger of L..
PU
06/15DIASORIN S P A : launches the first fully automated CLIA high-throughput solution for diag..
PU
06/03DIASORIN S P A : signs agreements with Unifarma and Alliance Healthcare for the distributi..
PU
05/25DIASORIN S P A : Launches Antigen Test To Detect COVID-19 Infection
MT
05/25DIASORIN : launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect C..
PU
05/24DIASORIN S.P.A. : Ex-dividend day for final dividend
FA
More news
News in other languages on DIASORIN S.P.A.
06:32aBORSA : Milano prosegue sopra la parità
10/19BORSA : Milano cauta, WS sopra la parità
10/13BORSA I. EQUITY MTF : in luce Tim
10/13BORSA : Milano piatta, WS debole
10/13BORSA : Milano poco mossa, WS vista cauta
More news
Chart DIASORIN S.P.A.
Duration : Period :
DiaSorin S.p.A. Technical Analysis Chart | DIA | IT0003492391 | MarketScreener
Technical analysis trends DIASORIN S.P.A.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 181,50 €
Average target price 176,65 €
Spread / Average Target -2,67%
EPS Revisions
Managers and Directors
Carlo Rosa Chief Executive Officer, Executive Director & GM
Piergiorgio Pedron Chief Financial Officer & Senior Corporate VP
Gustavo Denegri Chairman
Franco Moscetti Independent Director
Giuseppe Alessandria Lead Independent Director
Sector and Competitors